Literature DB >> 30078108

Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.

Gulten Tuncel1, Rasime Kalkan2.   

Abstract

Glioblastoma multiforme (GBM) is the most malignant form of the brain tumors and shows different genetic and epigenetic abnormalities. Gene amplification, genetic instability, disruption of apoptotic pathways, deregulated oncogene expression, invasive phenotypical changes, abnormal angiogenesis, and epigenetic changes have all been described in GBMs. These abnormalities indicate that a number of different signaling pathways are deregulated in GBM. Increasing number of studies provide a better understanding of the tumor biology, genetic, and epigenetic background of the GBM. Also, current research provides us useful approaches in designing novel therapies for GBM. In this review, we summarize the receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network, focusing on the potential molecular targets for anti-signaling molecular therapies in this pathway.

Entities:  

Keywords:  Glioblastoma; Molecular target; PI 3 kinase-Akt; Ras; Receptor tyrosine kinase

Mesh:

Substances:

Year:  2018        PMID: 30078108     DOI: 10.1007/s12032-018-1185-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  110 in total

1.  Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells.

Authors:  Nikki Charles; Tatsuya Ozawa; Massimo Squatrito; Anne-Marie Bleau; Cameron W Brennan; Dolores Hambardzumyan; Eric C Holland
Journal:  Cell Stem Cell       Date:  2010-02-05       Impact factor: 24.633

Review 2.  Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.

Authors:  Mayumi Ono; Michihiko Kuwano
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

3.  The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.

Authors:  Jenna Kahn; Thomas J Hayman; Muhammad Jamal; Barbara H Rath; Tamalee Kramp; Kevin Camphausen; Philip J Tofilon
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 4.  Temozolomide and treatment of malignant glioma.

Authors:  H S Friedman; T Kerby; H Calvert
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

5.  Downregulation of RUNX3 and TES by hypermethylation in glioblastoma.

Authors:  W Mueller; C L Nutt; M Ehrich; M J Riemenschneider; A von Deimling; D van den Boom; D N Louis
Journal:  Oncogene       Date:  2006-08-14       Impact factor: 9.867

6.  Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation.

Authors:  Sreelatha Gopinath; Rama Rao Malla; Christopher S Gondi; Kiranmai Alapati; Daniel Fassett; Jeffrey D Klopfenstein; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

7.  EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms.

Authors:  C A Del Vecchio; C P Giacomini; H Vogel; K C Jensen; T Florio; A Merlo; J R Pollack; A J Wong
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

Review 8.  Recent advances in the molecular understanding of glioblastoma.

Authors:  Fonnet E Bleeker; Remco J Molenaar; Sieger Leenstra
Journal:  J Neurooncol       Date:  2012-01-20       Impact factor: 4.130

Review 9.  Targeting RTK Signaling Pathways in Cancer.

Authors:  Tarik Regad
Journal:  Cancers (Basel)       Date:  2015-09-03       Impact factor: 6.639

10.  Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

Authors:  Tim F Cloughesy; Koji Yoshimoto; Phioanh Nghiemphu; Kevin Brown; Julie Dang; Shaojun Zhu; Teli Hsueh; Yinan Chen; Wei Wang; David Youngkin; Linda Liau; Neil Martin; Don Becker; Marvin Bergsneider; Albert Lai; Richard Green; Tom Oglesby; Michael Koleto; Jeff Trent; Steve Horvath; Paul S Mischel; Ingo K Mellinghoff; Charles L Sawyers
Journal:  PLoS Med       Date:  2008-01-22       Impact factor: 11.069

View more
  14 in total

Review 1.  RETRACTED ARTICLE: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Authors:  Fei Xu; Lixin Na; Yanfei Li; Linjun Chen
Journal:  Cell Biosci       Date:  2020-04-01       Impact factor: 7.133

2.  Identification of hub genes and small-molecule compounds in medulloblastoma by integrated bioinformatic analyses.

Authors:  Zhendong Liu; Ruotian Zhang; Zhenying Sun; Jiawei Yao; Penglei Yao; Xin Chen; Xinzhuang Wang; Ming Gao; Jinzhao Wan; Yiming Du; Shiguang Zhao
Journal:  PeerJ       Date:  2020-04-14       Impact factor: 2.984

3.  Anti-Inflammatory Effects of Huangqin Decoction on Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice Through Regulation of the Gut Microbiota and Suppression of the Ras-PI3K-Akt-HIF-1α and NF-κB Pathways.

Authors:  Min-Yao Li; Hui-Juan Luo; Xue Wu; Yu-Hong Liu; Yu-Xuan Gan; Nan Xu; Yao-Min Zhang; Shu-Hua Zhang; Chang-Lin Zhou; Zi-Ren Su; Xiao-Qi Huang; Xue-Bao Zheng
Journal:  Front Pharmacol       Date:  2020-01-20       Impact factor: 5.810

4.  Analysis of miR-9-5p, miR-124-3p, miR-21-5p, miR-138-5p, and miR-1-3p in Glioblastoma Cell Lines and Extracellular Vesicles.

Authors:  Alja Zottel; Neja Šamec; Ana Kump; Lucija Raspor Raspor Dall'Olio; Pia Pužar Dominkuš; Rok Romih; Samo Hudoklin; Jernej Mlakar; Daniil Nikitin; Maxim Sorokin; Anton Buzdin; Ivana Jovčevska; Radovan Komel
Journal:  Int J Mol Sci       Date:  2020-11-11       Impact factor: 5.923

5.  MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways.

Authors:  Xu Zhang; Jie Wang; Yifeng Wang; Guanzheng Liu; Huan Li; Jiefeng Yu; Runqiu Wu; Jun Liang; Rutong Yu; Xuejiao Liu
Journal:  Front Oncol       Date:  2021-01-14       Impact factor: 5.738

6.  LRIG3 Suppresses Angiogenesis by Regulating the PI3K/AKT/VEGFA Signaling Pathway in Glioma.

Authors:  Chenghao Peng; Hanmin Chen; Youwei Li; Hang Yang; Peizhong Qin; Baojun Ma; Qiuhong Duan; Baofeng Wang; Feng Mao; Dongsheng Guo
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

Review 7.  Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Authors:  Fei Xu; Lixin Na; Yanfei Li; Linjun Chen
Journal:  Cell Biosci       Date:  2020-04-01       Impact factor: 7.133

8.  Involvement of Phosphatase and Tensin Homolog in Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Blockade of Glioblastoma.

Authors:  Songlin Liu; Dun Yuan; Yifeng Li; Qi Qi; Bingzhong Guo; Shun Yang; Jilin Zhou; Lu Xu; Tiange Chen; Chenxing Yang; Junyu Liu; Buyan Li; Li Yao; Weixi Jiang
Journal:  Front Pharmacol       Date:  2019-11-07       Impact factor: 5.810

Review 9.  Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.

Authors:  Pamela Bielli; Vittoria Pagliarini; Marco Pieraccioli; Cinzia Caggiano; Claudio Sette
Journal:  Cells       Date:  2019-12-18       Impact factor: 6.600

Review 10.  Anti-neoplastic Potential of Flavonoids and Polysaccharide Phytochemicals in Glioblastoma.

Authors:  Ayesha Atiq; Ishwar Parhar
Journal:  Molecules       Date:  2020-10-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.